Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
Status:
Completed
Trial end date:
2019-12-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn about the effect atorvastatin on blood vessel function
and Raynaud symptoms in patients with early diffuse systemic sclerosis.
Systemic sclerosis is a disease characterized by blood vessel injury, immune system
activation and fibrosis. Blood vessel injury is thought to be important early in the disease.
Blood vessel complications of systemic sclerosis include Raynaud phenomena, finger and toe
ulcers, and pulmonary hypertension. While atorvastatin reduces cholesterol, it is recognized
to have many effects beyond cholesterol reduction. These include improvement of blood vessel
function and reduction of fibrosis. We hypothesize that treatment with atorvastatin over 16
weeks will improve blood vessel function and Raynaud symptom in patients with early diffuse
systemic sclerosis. We hope that by targeting therapy early in the disease we may delay blood
vessel changes and improve Raynaud symptoms.
Phase:
Phase 2
Details
Lead Sponsor:
Robyn T. Domsic, MD, MPH University of Pittsburgh
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)